PD-L1 Is a Direct Target of Cancer-Foxp3 in Pancreatic Ductal Adenocarcinoma (PDAC), and Combined Immunotherapy With Antibodies Against PD-L1 and CCL5 Is Effective in the Treatment of PDAC
Signal Transduction and Targeted Therapy - United Kingdom
doi 10.1038/s41392-020-0144-8
Full Text
Open PDFAbstract
Available in full text
Date
April 17, 2020
Authors
Publisher
Springer Science and Business Media LLC